PT1050301E - Medicinal compositions containing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol - Google Patents
Medicinal compositions containing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol Download PDFInfo
- Publication number
- PT1050301E PT1050301E PT99900351T PT99900351T PT1050301E PT 1050301 E PT1050301 E PT 1050301E PT 99900351 T PT99900351 T PT 99900351T PT 99900351 T PT99900351 T PT 99900351T PT 1050301 E PT1050301 E PT 1050301E
- Authority
- PT
- Portugal
- Prior art keywords
- octylphenyl
- diol
- amino
- propane
- ethyl
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Rheumatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a pharmaceutical composition containing 2-amino-2-Ä2-(4-octylphenyl)ethylÜpropane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof, and cyclodextrin as a stabilizer, and where necessary, saccharide, which can be prepared into a liquid agent, and which is useful for the suppression of rejection in organ or bone marrow transplantation, immunosuppressive sustention therapy therefor or the treatment of autoimmune diseases.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10008045A JPH11209277A (en) | 1998-01-19 | 1998-01-19 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1050301E true PT1050301E (en) | 2009-06-16 |
Family
ID=11682381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT99900351T PT1050301E (en) | 1998-01-19 | 1999-01-19 | Medicinal compositions containing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1050301B1 (en) |
JP (2) | JPH11209277A (en) |
KR (1) | KR100546450B1 (en) |
CN (1) | CN1191062C (en) |
AT (1) | ATE426402T1 (en) |
AU (1) | AU1891199A (en) |
BR (1) | BR9907099A (en) |
CA (1) | CA2319217C (en) |
DE (1) | DE69940633D1 (en) |
ES (1) | ES2323199T3 (en) |
IL (1) | IL137362A (en) |
NZ (1) | NZ506408A (en) |
PT (1) | PT1050301E (en) |
RU (1) | RU2204387C2 (en) |
WO (1) | WO1999036065A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4627356B2 (en) | 1999-06-30 | 2011-02-09 | 松森 昭 | Drugs for preventing or treating viral myocarditis |
WO2002018395A1 (en) | 2000-08-31 | 2002-03-07 | Merck & Co., Inc. | Phosphate derivatives as immunoregulatory agents |
JP2007217438A (en) * | 2001-07-17 | 2007-08-30 | Shionogi & Co Ltd | Medical preparation for injection |
TWI232102B (en) * | 2001-07-17 | 2005-05-11 | Shionogi & Co | A pharmaceutical formulation for injection |
GB0125443D0 (en) | 2001-10-23 | 2001-12-12 | Novartis Ag | Organic Compounds |
KR100836547B1 (en) | 2002-01-11 | 2008-06-10 | 상꾜 가부시키가이샤 | Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
US20040014662A1 (en) | 2002-05-08 | 2004-01-22 | Per Lindquist | Modulation of neural stem cells and neural progenitor cells |
DE122011100047I1 (en) * | 2003-04-08 | 2011-12-15 | Mitsubishi Tanabe Pharma Corp | Solid pharmaceutical dosage forms containing a S1P receptor agonist and a sugar alcohol. |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
EP1484057A1 (en) * | 2003-06-06 | 2004-12-08 | Aventis Pharma Deutschland GmbH | Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain |
US7524887B2 (en) | 2003-06-06 | 2009-04-28 | Sanofi-Aventis Deutschland Gmbh | 2-amino-1,3-propanediol compounds for the treatment of acute pain |
BRPI0507944A (en) | 2004-02-24 | 2007-07-24 | Sankyo Co | pharmaceutical composition |
RU2402324C2 (en) * | 2004-07-30 | 2010-10-27 | Новартис Аг | 2-amino-1,3-propanediol compositions |
SI2278960T2 (en) * | 2008-03-17 | 2020-02-28 | Actelion Pharmaceuticals Ltd. | Dosing regimen for a selective sip1 receptor agonist |
US8766005B2 (en) * | 2009-07-24 | 2014-07-01 | Ratiopharm Gmbh | Process for producing fingolimod salts |
AR085749A1 (en) * | 2011-04-01 | 2013-10-23 | Novartis Ag | FORMULATIONS |
DE102012101680A1 (en) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmaceutical preparation containing an antiviral dihydroquinazoline derivative |
US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
KR20200127222A (en) * | 2018-03-01 | 2020-11-10 | 이시하라 산교 가부시끼가이샤 | Pharmaceutical composition with excellent storage stability |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51133960A (en) * | 1975-05-16 | 1976-11-20 | Kao Corp | Defoaming method |
JPS5718607A (en) * | 1980-07-07 | 1982-01-30 | Kaken Pharmaceut Co Ltd | Injection preparation |
JPS58148816A (en) * | 1982-02-27 | 1983-09-05 | Nippon Zenyaku Kogyo Kk | Low irritant thiamulin injection |
JPS63253022A (en) * | 1987-04-08 | 1988-10-20 | Nitto Electric Ind Co Ltd | Baclofen pharmaceutical for external use |
IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
EP0335545B2 (en) * | 1988-03-29 | 1998-09-23 | University Of Florida | Pharmaceutical formulations for parenteral use |
JP3054776B2 (en) * | 1990-04-13 | 2000-06-19 | 丸善製薬株式会社 | Method for controlling sweetness of glycyrrhizin |
TW200402B (en) * | 1990-08-13 | 1993-02-21 | Senju Pharma Co | |
JPH0616547A (en) * | 1992-07-01 | 1994-01-25 | Wakamoto Pharmaceut Co Ltd | Antiphlogistic ophthalmic solution |
KR0155015B1 (en) * | 1992-10-21 | 1998-12-01 | 고우야 마사시 | 2-amino-1,3-propanediol compound and immunosuppressant |
JP2879395B2 (en) * | 1992-10-26 | 1999-04-05 | 富士写真フイルム株式会社 | Anticancer composition containing rhodacyanine compound and cyclodextrin |
JPH07228532A (en) * | 1993-04-22 | 1995-08-29 | Senju Pharmaceut Co Ltd | Water-soluble solution, method for improving solubility of its active ingredient and stabilization thereof |
JPH07316065A (en) * | 1994-05-25 | 1995-12-05 | Fujisawa Pharmaceut Co Ltd | Pharmaceutical preparation of fr 901469 substance |
ES2171191T3 (en) * | 1994-08-22 | 2002-09-01 | Mitsubishi Pharma Corp | COMPOSITE OF BENZENE AND MEDICINAL USE OF THE SAME. |
JPH0859483A (en) * | 1994-08-25 | 1996-03-05 | Higeta Shoyu Co Ltd | Anti-mycotic preparation |
JPH08175985A (en) * | 1994-12-26 | 1996-07-09 | Lion Corp | Ophthalmic solution |
JP2002241272A (en) * | 1996-07-18 | 2002-08-28 | Mitsubishi Pharma Corp | Medicinal composition |
-
1998
- 1998-01-19 JP JP10008045A patent/JPH11209277A/en active Pending
-
1999
- 1999-01-19 JP JP2000539838A patent/JP4434486B2/en not_active Expired - Lifetime
- 1999-01-19 PT PT99900351T patent/PT1050301E/en unknown
- 1999-01-19 ES ES99900351T patent/ES2323199T3/en not_active Expired - Lifetime
- 1999-01-19 BR BR9907099-5A patent/BR9907099A/en not_active Application Discontinuation
- 1999-01-19 RU RU2000121989/14A patent/RU2204387C2/en not_active IP Right Cessation
- 1999-01-19 DE DE69940633T patent/DE69940633D1/en not_active Expired - Lifetime
- 1999-01-19 CN CNB998041645A patent/CN1191062C/en not_active Expired - Fee Related
- 1999-01-19 IL IL13736299A patent/IL137362A/en not_active IP Right Cessation
- 1999-01-19 KR KR1020007007911A patent/KR100546450B1/en not_active IP Right Cessation
- 1999-01-19 CA CA002319217A patent/CA2319217C/en not_active Expired - Fee Related
- 1999-01-19 NZ NZ506408A patent/NZ506408A/en unknown
- 1999-01-19 EP EP99900351A patent/EP1050301B1/en not_active Expired - Lifetime
- 1999-01-19 AU AU18911/99A patent/AU1891199A/en not_active Abandoned
- 1999-01-19 AT AT99900351T patent/ATE426402T1/en active
- 1999-01-19 WO PCT/JP1999/000152 patent/WO1999036065A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
DE69940633D1 (en) | 2009-05-07 |
JP4434486B2 (en) | 2010-03-17 |
EP1050301A4 (en) | 2004-11-17 |
RU2204387C2 (en) | 2003-05-20 |
ATE426402T1 (en) | 2009-04-15 |
IL137362A0 (en) | 2001-07-24 |
WO1999036065A1 (en) | 1999-07-22 |
CA2319217C (en) | 2008-03-25 |
KR20010034240A (en) | 2001-04-25 |
ES2323199T3 (en) | 2009-07-08 |
IL137362A (en) | 2003-06-24 |
CN1294511A (en) | 2001-05-09 |
EP1050301B1 (en) | 2009-03-25 |
AU1891199A (en) | 1999-08-02 |
KR100546450B1 (en) | 2006-01-26 |
JPH11209277A (en) | 1999-08-03 |
NZ506408A (en) | 2002-09-27 |
EP1050301A1 (en) | 2000-11-08 |
CN1191062C (en) | 2005-03-02 |
CA2319217A1 (en) | 1999-07-22 |
BR9907099A (en) | 2001-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1050301E (en) | Medicinal compositions containing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol | |
HK1027039A1 (en) | Pharmaceutical composition comprising 2-amino-2-[2-(4- octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharidee | |
RU95102778A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for osseous tissue loss inhibition and serum cholesterol level decrease, pharmaceutical preparation containing 2-phenyl-3-aroylbenzothiophene | |
WO2002043750A3 (en) | Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations | |
CA2304704A1 (en) | Formulations and methods for reducing toxicity of antineoplastic agents | |
BR9810312A (en) | Pharmaceutical composition that has marked antitumor activity and / or reduced side effects containing an antitumor agent and a derivative of hydroxy acid | |
DE69828603D1 (en) | Use of α-glycosylceramides for the preparation of a therapeutic agent for the treatment of autoimmune diseases | |
BR0008590A (en) | Polymeric delivery agent, composition, unit dosage form, method for administering a biologically active agent to an animal requiring the agent, method for preparing a composition; it's composed | |
EP1002792A4 (en) | 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same | |
BR9813373A (en) | Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and, processes for effecting immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease in a patient | |
EP1787982A3 (en) | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | |
ES2179910T3 (en) | CRYSTAL MODIFICATION OF THE CDCH, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT. | |
DE60000288D1 (en) | MONODISPERSE FORMULATIONS CONTAINING HEXAMERS ACYLATED INSULIN ANALOGS | |
CA2392168A1 (en) | Vitamin d analogues | |
BR0010983A (en) | Preparations for the application of anti-inflammatory agents | |
BR9810452A (en) | New combination of asthma drugs | |
BR0011845A (en) | Pharmaceutical complex | |
AU2002333536A1 (en) | Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof | |
EP0743068A3 (en) | Composition for inhibiting bone loss containing vanadyl sulfate | |
BR0016646A (en) | Method for treating a patient suffering from pain, and pharmaceutical composition | |
TH25306B (en) | Method of use for inhibition of bone loss and reduction of serum cholesterol. | |
TH25306A (en) | Method of use for inhibition of bone loss and reduction of serum cholesterol. | |
BR9714774A (en) | Soluble paclitaxel prodrugs | |
TH13118EX (en) | Spongy material mainly composed of hyaluronic acid or its derivatives and is used in laparoscopic surgery. |